Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome b (mitochondrially encoded) is a transmembrane protein subunit of complex III—the ubiquinol-cytochrome c reductase complex—within the mitochondrial inner membrane. It mediates electron transfer from ubiquinol to cytochrome c, facilitating the generation of the proton-motive force for ATP synthesis during oxidative phosphorylation. Mutations in MT-CYB disrupt complex III function, leading to mitochondrial deficiencies with varied clinical manifestations, including muscle weakness, exercise intolerance, cardiomyopathy, neurodegenerative disorders, and multisystem disease. MT-CYB is also pharmacologically relevant as a target for drugs that modulate mitochondrial electron transport, with mutation-specific sensitivity to certain therapeutics such as atovaquone and clomipramine.
Inhibition of electron transfer at complex III (e.g., atovaquone and clomipramine bind to ubiquinol or inhibitor sites, impeding electron flow and ATP production)\nModulation of proton gradient, energy production, and redox balance
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome b (mitochondrially encoded) (MT-CYB).